Primary Immune Thrombocytopenia Clinical Trial
Official title:
Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP): a Single-arm, Multi-centre, Observational Study
The project was undertaking by Qilu Hospital of Shandong University and other well-known hospitals in China. Aims at evaluating effectiveness and safety of avatrombopag in the treatment of primary immune thrombocytopenia.
The investigators are undertakingSingle-arm, multi-Centre, Observational study of 400 Patients with primary immune thrombocytopenia (ITP) from Qilu Hospital of Shandong University and other well-known hospitals in China. ITP patients will be given one tablet (20 mg) of avatrombopag daily.If the platelet count is higher than 150×10^9/L, the dose should be reduced. Prolonged dosing intervals or a combination of reduced daily dose are preferred.If the drug was taken for ≥1 week and the platelet count was still less than 30×10^9/L, the dosage should be increased. The maximum dose is 40 mg daily. Aplatelet count,AE, laboratory parameters, ECG, vital signs and other symptoms will be evaluated before and after treatment. Adverse events will be recorded throughout the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06466824 -
Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010
|
||
| Completed |
NCT05621330 -
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
|
Phase 3 | |
| Active, not recruiting |
NCT04278924 -
A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
|
Phase 2 | |
| Recruiting |
NCT06148389 -
The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT04812925 -
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
|
Phase 3 | |
| Recruiting |
NCT06107582 -
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
|
||
| Recruiting |
NCT05371743 -
Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purpura (ITP)
|
||
| Not yet recruiting |
NCT05311930 -
Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients
|
Phase 4 | |
| Not yet recruiting |
NCT05333861 -
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
|
||
| Completed |
NCT03102593 -
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
|
Phase 2 | |
| Completed |
NCT06071520 -
Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study
|
||
| Terminated |
NCT04224688 -
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
| Active, not recruiting |
NCT04225156 -
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
|
Phase 3 | |
| Completed |
NCT05551624 -
Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine
|
Early Phase 1 | |
| Recruiting |
NCT05422365 -
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
|
Phase 3 | |
| Terminated |
NCT03275740 -
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
|
Phase 1 | |
| Terminated |
NCT04596995 -
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
| Terminated |
NCT04200456 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
| Recruiting |
NCT05653219 -
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
|
Phase 3 | |
| Completed |
NCT01727232 -
Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia
|
N/A |